|
Pemetrexed (Pem) with pembrolizumab (Pembro) maintenance: A post hoc subgroup safety analysis of KEYNOTE-189. |
|
|
Stock and Other Ownership Interests - amphera |
Consulting or Advisory Role - Amphera; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Roche; Takeda |
Patents, Royalties, Other Intellectual Property - cdendritic cel based immunotherapy (Inst); combination immunotherapy (Inst); proteomics in nsclc (Inst) |
Travel, Accommodations, Expenses - MSD Oncology |
|
|
Consulting or Advisory Role - Dracen; EMD Serono; Novartis |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst) |
|
|
|
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Genentech/Roche |
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Pfizer; Takeda; Xcovery |
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche |
Other Relationship - AstraZeneca |